Generic drug maker Hetero has launched biosimilar drug Bevacizumab for the treatment of metastatic colorectal cancer (mCRC) under the brand Cizumab. The product was approved by the Drug Controller General of India and was recommended as a first line treatment for mCRC, the Hyderabad-based company said in a release issued here on Monday. The product will be manufactured in Hetero’s biologics facility here.